1. Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives
    Gebremedhin S. Hailu et al, 2017, J. Med. Chem. CrossRef
  2. Epigenetic control of gene function in schistosomes: a source of therapeutic targets?
    Alejandro Cabezas-Cruz et al, 2014, Front. Genet. CrossRef
  3. Structure-Based Design and Synthesis of Novel Inhibitors Targeting HDAC8 fromSchistosoma mansonifor the Treatment of Schistosomiasis
    Tino Heimburg et al, 2016, J. Med. Chem. CrossRef
  4. Histone Deacetylase Inhibitors as Anticancer Drugs
    Tomas Eckschlager et al, 2017, IJMS CrossRef
  5. A Novel Class of Schistosoma mansoni Histone Deacetylase 8 (HDAC8) Inhibitors Identified by Structure-Based Virtual Screening and In Vitro Testing
    Conrad Simoben et al, 2018, Molecules CrossRef
  6. The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
    , 2018, Molecules CrossRef
  7. Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets
    Vera Miranda-Gonçalves et al, 2018, Front. Genet. CrossRef
  8. Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment
    Dimitrios Schizas et al, 2018, WJG CrossRef
  9. Expression of HDAC8 indicates poor prognosis of esophageal squamous cell carcinoma and progression to advanced stage
    Cheng Yufeng et al, 2019, IJCO CrossRef
  10. Epigenetic Changes as a Target in Aging Haematopoietic Stem Cells and Age-Related Malignancies
    Sonja C. Buisman et al, 2019, Cells CrossRef
  11. Synergistic Effect of Epigenetic Inhibitors Decitabine and Suberoylanilide Hydroxamic Acid on Colorectal Cancer In vitro
    Sonia Abou Najem et al, 2019, CMP CrossRef
  12. Induction of Apoptosis and Autophagy in Breast Cancer Cells by a Novel HDAC8 Inhibitor
    Chang-Fang Chiu et al, 2019, Biomolecules CrossRef
  13. Genetic Segmentation and Targeted Therapeutics for Multiple Myeloma
    Louis Williams et al, 2019 CrossRef
  14. Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
    Faria Sultana et al, 2020, CMC CrossRef
  15. Combination of Decitabine and Entinostat Synergistically Inhibits Urothelial Bladder Cancer Cells via Activation of FoxO1.
    Wolfgang Schulz, 0 CrossRef
  16. HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women
    Sara S. Oltra et al, 2020, Cancers CrossRef
  17. Targeting Epigenetic Dependencies in Solid Tumors: Evolutionary Landscape Beyond Germ Layers Origin
    Francesca Citron et al, 2020, Cancers CrossRef
  18. Dual-target inhibitors based on HDACs: Novel antitumor agents for cancer therapy
    Tingting Liu et al, 2020, J. Med. Chem. CrossRef
  19. Largazole is a Brain-Penetrant Class I HDAC Inhibitor with Extended Applicability to Glioblastoma and CNS Diseases
    Fatma H. Al-Awadhi et al, 2020, ACS Chem. Neurosci. CrossRef
  20. In Vitro Assessment of the Genotoxic Hazard of Novel Hydroxamic Acid- and Benzamide-Type Histone Deacetylase Inhibitors (HDACi).
    Wolfgang Schulz, 0 CrossRef
  21. Down expression of lnc-BMP1-1 decreases that of Caveolin-1 is associated with the lung cancer susceptibility and cigarette smoking history
    Xiaoxuan Ling et al, 2020, Aging CrossRef
  22. HDAC8: A Promising Therapeutic Target for Acute Myeloid Leukemia
    Marco Spreafico et al, 2020, Front. Cell Dev. Biol. CrossRef
  23. B7-H3-targeted Radioimmunotherapy of Human Cancer
    Benjamin B. Kasten et al, 2020, CMC CrossRef
  24. The Relationship between Histone Deacetylase (HDACs) and Gastric Cancer
    珊 徐, 2020, ACM CrossRef
  25. Histone Deacetylase Inhibitors as Therapeutic Interventions on Cervical Cancer Induced by Human Papillomavirus
    Natália Lourenço de Freitas et al, 2021, Front. Cell Dev. Biol. CrossRef
  26. Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities.
    Nikolaos Garmpis et al, 2021, J Pers Med CrossRef
  27. Binding Free Energy (BFE) Calculations and Quantitative Structure–Activity Relationship (QSAR) Analysis of Schistosoma mansoni Histone Deacetylase 8 (smHDAC8) Inhibitors
    Conrad V. Simoben et al, 2021, Molecules CrossRef
  28. Improved HDAC Inhibition, Stronger Cytotoxic Effect and Higher Selectivity against Leukemias and Lymphomas of Novel, Tricyclic Vorinostat Analogues
    Bartosz Bieszczad et al, 2021, Pharmaceuticals CrossRef
  29. β-Carboline tethered cinnamoyl 2-aminobenzamides as class I selective HDAC inhibitors: Design, synthesis, antiproliferative activity and modelling studies
    Hari Krishna Namballa et al, 2021, Bioorganic Chemistry CrossRef
  30. Acetylation in Tumor Immune Evasion Regulation
    Jun Lu et al, 2021, Front. Pharmacol. CrossRef
  31. Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer
    Bayley G. Matthews et al, 2021, Cancers CrossRef
  32. Propolin G-Suppressed Epithelial-to-Mesenchymal Transition in Triple-Negative Breast Cancer Cells via Glycogen Synthase Kinase 3β-Mediated Snail and HDAC6-Regulated Vimentin Degradation
    Jih-Tung Pai et al, 2022, IJMS CrossRef
  33. Comprehensive Analysis of the Differential Expression and Prognostic Value of Histone Deacetylases in Glioma
    Jinwei Li et al, 2022, Front. Cell Dev. Biol. CrossRef
  34. Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
    Peijun Cao et al, 2022, Front. Chem. CrossRef
  35. High Histone Deacetylase 2/3 Expression in Non-Functioning Pituitary Tumors
    Wenxiu Zhao et al, 2022, Front. Oncol. CrossRef
  36. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo
    Christian A. Hassig et al, 2008 CrossRef
  37. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications.
    David S Schrump, 2009, Clin. Cancer Res. CrossRef
  38. null
    Paul A. Marks, 2013 CrossRef
  39. Characterization of the HDAC1 Complex That Regulates the Sensitivity of Cancer Cells to Oxidative Stress
    Takuya Kato et al, 2009 CrossRef
  40. Epigenetic Modulators as Treatment Alternative to Diverse Types of Cancer
    Jorseth Rodelo Gutiérrez et al, 2022, CMC CrossRef
  41. Histone modification and histone modification-targeted anti-cancer drugs in breast cancer: Fundamentals and beyond
    Jianwei Feng et al, 2022, Front. Pharmacol. CrossRef
  42. Pathological Role of HDAC8: Cancer and Beyond
    Ji Yoon Kim et al, 2022, Cells CrossRef
  43. Structure-Based Discovery of Selective Histone Deacetylase 8 Degraders with Potent Anticancer Activity
    Jinbo Huang et al, 2022, J. Med. Chem. CrossRef
  44. HDACs as an emerging target in endocrine tumors: a comprehensive review
    Eckhard Klieser et al, 2023, Expert Review of Endocrinology & Metabolism CrossRef
  45. Synthesis of N‐aminophalimides derived from α‐amino acids: Theoretical study to find them as HDAC8 inhibitors by docking simulations and in vitro assays
    José Eduardo Guzmán Ramírez et al, 2023, Chem Biol Drug Des CrossRef
  46. Progress in the research of epigenetic regulators in cancer therapy
    LongJiang DI et al, 2023, Sci. Sin.-Vitae CrossRef
  47. Expression of acetylated histones H3 and H4 and histone deacetylase enzymes HDAC1, HDAC2 and HDAC6 in simple mammary carcinomas of female dogs
    Igor Luiz Salardani Senhorello et al, 2023, Front. Genet. CrossRef